Audentes Therapeutics (BOLD) is Initiated by Wedbush to Outperform, Price Target at $20

Audentes Therapeutics (BOLD) was Initiated by Wedbush to “Outperform” and the brokerage firm has set the Price Target at $20. Wedbush advised their investors in a research report released on Aug 15, 2016.

Many Wall Street Analysts have commented on Audentes Therapeutics. Audentes Therapeutics was Initiated by Piper Jaffray to “Overweight” on Aug 15, 2016.

Audentes Therapeutics

Leave a Reply

Audentes Therapeutics - Is it time to Sell?

Top Brokerage Firms are advising their investors on Audentes Therapeutics. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.